Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

118.31 +5.20 (+4.60%)
At close: 4:00:00 PM EDT
115.27 -3.04 (-2.57%)
After hours: 5:52:32 PM EDT
Trade RGEN on Coinbase
Chart Range Bar
Loading chart for RGEN
  • Previous Close 113.11
  • Open 114.08
  • Bid 117.99 x 400
  • Ask 118.43 x 800
  • Day's Range 112.97 - 118.42
  • 52 Week Range 109.50 - 175.77
  • Volume 1,609,810
  • Avg. Volume 917,242
  • Market Cap (intraday) 6.673B
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) 137.57
  • EPS (TTM) 0.86
  • Earnings Date May 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 179.78

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

2,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview: RGEN

Trailing total returns as of 4/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGEN
27.80%
S&P 500 (^GSPC)
5.31%

1-Year Return

RGEN
14.26%
S&P 500 (^GSPC)
29.45%

3-Year Return

RGEN
21.97%
S&P 500 (^GSPC)
72.90%

5-Year Return

RGEN
44.12%
S&P 500 (^GSPC)
72.42%

Earnings Trends: RGEN

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 197.91M
Earnings 27.69M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
50M
100M
150M

Analyst Insights: RGEN

View More

Analyst Price Targets

140.00
179.78 Average
118.31 Current
220.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/20/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Hold
Price Action Lowers
Price Target 165 -> 145

Statistics: RGEN

View More

Valuation Measures

Annual
As of 4/29/2026
  • Market Cap

    6.38B

  • Enterprise Value

    6.31B

  • Trailing P/E

    131.62

  • Forward P/E

    57.47

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.67

  • Price/Book (mrq)

    3.03

  • Enterprise Value/Revenue

    8.54

  • Enterprise Value/EBITDA

    34.87

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.62%

  • Return on Assets (ttm)

    0.99%

  • Return on Equity (ttm)

    2.40%

  • Revenue (ttm)

    738.26M

  • Net Income Avi to Common (ttm)

    48.89M

  • Diluted EPS (ttm)

    0.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    767.63M

  • Total Debt/Equity (mrq)

    32.76%

  • Levered Free Cash Flow (ttm)

    76.07M

Compare To: RGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: RGEN

Fair Value

118.31 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: RGEN

View More
  • Lowering target price to $112.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $112.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
  • Raising target price to $126.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $126.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
  • Raising target price to $124.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $124.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
  • Lowering target price to $110.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $110.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: